Atlas Trials

The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

Clinical trial NCT04045730 · WITHDRAWN

Trial details

NCT number
NCT04045730
Sponsor
Yale University
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Pancreas Adenocarcinoma
Start date
2019-11-15
Primary completion
2019-12-31
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.